
Dr. Ajay Sharma is an experienced Medical Oncologist serving as Senior Director and Unit Head of Medical Oncology at Max Healthcare, with professional associations at Max Super Speciality Hospital, Shalimar Bagh and BLK-Max Super Speciality Hospital, New Delhi. His clinical practice focuses on the diagnosis and treatment of different types of cancers through specialised medical oncology services.
He completed his MBBS from Government Medical College, Jammu, followed by an MD in General Medicine from Sher-i-Kashmir Institute of Medical Sciences, Srinagar. He subsequently obtained a DNB in Medical Oncology from Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, and completed European certification in Medical Oncology in Amsterdam.
His clinical expertise includes chemotherapy, targeted therapy, immunotherapy and the management of different solid tumours and blood cancers. His areas of interest include breast cancer, lung cancer, gastrointestinal cancers, gynaecological cancers, genitourinary cancers, leukaemias, lymphomas and multiple myeloma.
Before joining Max Healthcare, Dr. Sharma held medical oncology positions at Rajiv Gandhi Cancer Institute and Research Centre and Action Cancer Hospital, New Delhi. He is also associated with professional organisations including the American Society of Clinical Oncology, European Society for Medical Oncology and the Indian Society of Medical and Paediatric Oncology.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Ajay Sharma for Medical Oncology treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Medical Oncology in India.
Dr. Ajay Sharma regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Ajay Sharma holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in DNB (Medical Oncology)
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
Targeted therapy, immunotherapy, and chemotherapy tailored to molecular profile for all stages.
Hormone therapy, HER2-targeted agents, chemotherapy, and CDK4/6 inhibitors across all subtypes.
Chemotherapy, targeted biologics (bevacizumab, cetuximab), and immunotherapy for GI malignancies.
Platinum-based chemotherapy, EGFR inhibitors, and PD-L1 checkpoint inhibitors.
R-CHOP, R-DHAP, ABVD, and checkpoint inhibitors for all histological subtypes.
Induction chemotherapy, targeted kinase inhibitors, and novel agent combinations for haematological malignancies.
Platinum/taxane-based regimens, PARP inhibitors (BRCA-mutated), and bevacizumab for ovarian and cervical cancers.
Immunotherapy (checkpoint inhibitors), targeted therapy, and hormonal agents for kidney, bladder, and prostate cancers.
Anthracycline-based first-line chemotherapy and trabectedin for advanced sarcomas.
Evidence-based systemic chemotherapy regimens delivered safely with meticulous toxicity management.
Precision oncology using small molecule inhibitors and monoclonal antibodies matched to tumour biology.
PD-1, PD-L1, and CTLA-4 inhibitors harnessing the immune system to fight cancer.
Comprehensive biomarker profiling to match each patient to the most effective treatment.
Endocrine manipulation and DNA-damage repair inhibitors for hormone-receptor-positive and BRCA-mutated cancers.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.